<DOC>
	<DOCNO>NCT02831491</DOCNO>
	<brief_summary>The main purpose study evaluate safety study drug ramucirumab combination weekly docetaxel participant stage IV non-small cell lung cancer ( NSCLC ) follow disease progression prior platinum-based chemotherapy .</brief_summary>
	<brief_title>A Study Ramucirumab ( LY3009806 ) Combination With Weekly Docetaxel Participants With Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>The participant disease progression prior platinumbased chemotherapy regimen locally advance metastatic NSCLC . Prior immunotherapy NSCLC allow . The participant Eastern Cooperative Oncology Group performance status 0 1 . The participant histologically cytologically confirm NSCLC . The participant metastatic NSCLC disease ( Stage IV ) time first dose study treatment . The participant measurable disease time first dose study treatment document computed tomography ( CT ) scan magnetic resonance imaging ( MRI ) . The participant resolution Grade ≤1 National Cancer Institutecommon terminology criterion adverse event ( NCICTCAE ) , Version 4.0 , clinically significant toxic effect prior locoregional therapy , surgery , anticancer therapy . The participant adequate organ function . The participant 's urine protein &lt; 2+ dipstick routine urinalysis ( UA ) . If urine dipstick routine analysis indicate proteinuria ≥2+ , 24hour urine must collect must demonstrate &lt; 2 gram protein 24 hour allow participation study . For male participant , sterile ( include vasectomy confirm post vasectomy semen analysis ) agree use highly effective method contraception ( 2 method prefer , per country requirement , whichever strict ) , donate sperm start first dose study treatment , study , least 6 month follow last dose study treatment country requirement , whichever longer . For female participant , surgically sterile , postmenopausal , agree use highly effective method contraception ( 2 method prefer , per country requirement , whichever strict ) study 6 month follow last dose study treatment country requirement , whichever longer . Female participant childbearing potential must negative serum urine pregnancy test within 72 hour prior first dose study treatment . The participant life expectancy ≥3 month . Prior therapy docetaxel ramucirumab . The participant receive 1 prior chemotherapy regimen locally advance metastatic NSCLC ; however , prior maintenance chemotherapy locally advance metastatic NSCLC allow . The participant 's tumour contain small cell lung cancer . The participant undergone major surgery within 28 day prior first dose study treatment , subcutaneous venous access device placement within 7 day prior first dose study treatment . Furthermore , participant postoperative bleeding complication wind complication surgical procedure perform last 2 month exclude . The participant bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection ( hemicolectomy extensive small intestine resection chronic diarrhea ) , Crohn 's disease , ulcerative colitis , chronic diarrhea . The participant peripheral neuropathy Grade ≥2 ( NCICTCAE v 4.0 ) . The participant elective plan major surgery course trial . The participant receive concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , chemoembolization , target therapy . The participant symptomatic , active , untreated central nervous system ( CNS ) metastasis . Brain metastases asymptomatic , stable require steroid use , previously treat radiation allow . The participant may evidence Grade ≥1 CNS hemorrhage base pretreatment MRI I.V . contrast CT scan ( perform within 21 day first dose study treatment ) . The participant radiologically document evidence major blood vessel invasion encasement cancer . The participant radiographic evidence intratumor cavitation , regardless tumor histology . The participant history uncontrolled hereditary acquire thrombotic disorder . The participant receive chronic therapy nonsteroidal antiinflammatory drug ( NSAIDs ; example , indomethacin , ibuprofen , naproxen , similar agent ) antiplatelet agent ( example , clopidogrel , ticlopidine , dipyridamole , anagrelide ) . Aspirin ( acetylsalicylic acid ) use dose 325 milligrams/day permit . Participants history gross hemoptysis ( define bright red blood ≥1/2 teaspoon ) within 2 month prior first dose study treatment . The participant clinically relevant congestive heart failure ( New York Heart Association Class IIIV ) symptomatic poorly control cardiac arrhythmia . The participant experience arterial thrombotic event , include myocardial infarction , unstable angina , cerebrovascular accident , transient ischemic attack , within 6 month prior first dose study treatment . The participant uncontrolled arterial hypertension ≥150 / ≥90 millimeter mercury despite standard medical management . The participant serious nonhealing wound , ulcer , bone fracture ≤28 day prior first dose study treatment . The participant significant bleeding disorder , vasculitis , experience Grade 34 gastrointestinal ( GI ) bleed within 3 month prior first dose study treatment . History GI perforation / fistula within 6 month prior first dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>metastatic</keyword>
</DOC>